《复牌公告》泰凌医药(01011.HK)现金加新股收购上海汉都52%
泰凌医药(01011.HK)公布,向WD Investment收购新药研发公司---上海汉都40%股权,初始代价3.12亿元,将透过发行4.27亿股代价股支付,发行价0.73元,较停牌前折让2.67%。同时,以现金代价3,000万美元认购上海汉都新股及可换股债券。完成後,公司共计持有上海汉都52%权益。
此外,公司将视乎市况配售不超过3.8亿股新股,每股作价0.73元,集资总额约2.78亿元。
上海汉都已研发若干具有自主知识产权、技术壁垒高的载药技术平台,开发解决未满足医学需求的创新药,主要以帕金森治疗为核心。完成後,WD Investment及其一致行动人士共计持有公司扩大後股本38%。
公司股份申请周四(11日)恢复买卖。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.